A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome

References

• Hogberg U. The World Health Report 2005: ‘‘make every mother and child count’’ – including Africans. Scand J Public Health. 2005;33:409–411.
   Google Scholar
• Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797–1803.
   Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–137.
   PubMed Web of Science ®Google Scholar
• Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376:631–644.
   PubMed Web of Science ®Google Scholar
• Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nat Clin Pract Nephrol. 2005;1:98–114.
   PubMedGoogle Scholar
• Roberts JM, Pearson GD, Cutler JA, et al. Summary of the NHBLI working group on research on hypertension during pregnancy. Hypertens Pregnancy. 2003;22:109–127.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol. 2009;200:481.e1–481.e7.
   Web of Science ®Google Scholar
• ACOG Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–1131.
   PubMed Web of Science ®Google Scholar
• Oliveira SM, Arcuri EA, Santos JL. Cuff width influence on blood pressure measurement during the pregnant-puerperal cycle. J Adv Nurs. 2002;38:180–189.
   PubMed Web of Science ®Google Scholar
• Reinders LW, Mos CN, Thornton C, et al. Time poor: rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. Hypertens Pregnancy. 2006;25:81–91.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466–480.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase–specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346–352.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005;90:4895–4903.
   PubMed Web of Science ®Google Scholar
• Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469–471.
   PubMed Web of Science ®Google Scholar
• Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem. 2010;43:768–770.
   PubMed Web of Science ®Google Scholar
• Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, et al. Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol. 2013;41:530–537.
   PubMed Web of Science ®Google Scholar
• Álvarez-Fernández I, Prieto B, Rodríguez V, et al. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 2014;52(8):1159–1168.
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected pre-eclampsia. Circulation. 2012;125:911–919.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161.e1–161.e11.
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.
   PubMed Web of Science ®Google Scholar
• Roche Diagnostics GmbH: Elecsys PlGF Immunoassay, Package Insert. 2015-11, V 8.0.. Available at: https://pim-eservices.roche.com/(S(aou3rto4kqllwta02cqhham0))/pi/en/Documents/GetDocument?documentId=b4d1d21e-03cf-e411-19b6-00215a9b0ba8. Accessed February 17, 2016.
   Google Scholar
• Sing T, Sander O, Beerenwinkel N, et al. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21:3940–3941.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
   PubMed Web of Science ®Google Scholar
• Ohkuchi A, Hirashima C, Takahashi K, et al. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19–31 weeks of gestation. Hypertens Res. 2013;36:1073–1080.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58.e1–58e8.
   Google Scholar
• Stepan H, Herraiz I, Schlembach D, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45:241–246.
   PubMed Web of Science ®Google Scholar
• Lai J, Garcia-Tizon Larroca S, Peeva G, et al. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn Ther. 2014;35:240–248.
   PubMed Web of Science ®Google Scholar